

SIMPLE YET BRILLIANT

veltio
pharma

“Porous Algae-Derived Cellulose: A Sustainable Excipient Enabling Drug Formulation”

01

PROBLEM


Poorly soluble drugs remain one of the biggest formulation challenges, limiting clinical efficiency and delaying drug development.

- Poor bioavailability
- Food effects
- High daily dosage
- Variable clinical efficiency

02

INNOVATION - SIMPLE & SCALABLE YET BRILLIANT

Veltio Pharma specializes in enhancing pharmaceutical formulations with a strong focus on sustainability. By transforming poorly soluble drugs into highly effective solid oral dosage forms using our proprietary porous cellulose platform, we improve patients' lives while minimizing environmental impact.



Porous cellulose derived from algae – a sustainable nanotechnology platform for oral formulations. Pure cellulose excipient.

Pharma Application patent:
WO2017216584A1, granted in US,
EU, KR, UK, JP and CA

03

BENEFITS

FOR BIOTECH & PHARMA:

- Advance projects without formulation barriers
- Reduced cost and faster development
- Lower the risk of delays or deprioritization
- Enable relevant systemic exposure in preclinical studies

FOR PATIENTS:

- Safe excipient – pure cellulose
- Lower doses
- Better treatment outcomes
- Improved quality of life

04

BUSINESS MODEL



PARTNERING

Work with pharma & biotech on preclinical candidate drugs. Drive value through service fees, milestones, and royalties.



IN-HOUSE PIPELINE

Improve formulations of marketed drugs. Out-license after clinical studies to bring better therapies to patients.



05

KEY ADVANTAGES

- High drug loading and capacity
- Solvent-free, dry powder formulation
- Low environmental impact
- Simple, scalable solution

06

VISION & MARKET

- Capacity for several joint development projects and own pipeline programs annually
- Revenues per project: 50–100+ MSEK
- Growth trajectory: ~1000 MSEK revenue projected by 2035

MEET THE TEAM



Albert Mihranyan
Founder



Stina Lundgren
CEO



Daniel Bergström
Chairman



Mats Johnson
BD

Based in Uppsala with lab facilities. Experienced leadership in pharma, R&D and commercialization. Expert consultants in legal, finance, IP, communication and CMC.

